Cara Therapeutics Inc (NAS:CARA)
$ 0.378 -0.0719 (-15.98%) Market Cap: 20.73 Mil Enterprise Value: -13.94 Mil PE Ratio: 0 PB Ratio: 37.80 GF Score: 35/100

Cara Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 07:00PM GMT
Release Date Price: $3.26 (-3.83%)
Dennis Ding
Jefferies LLC - Analyst

Hi, good afternoon, everybody. Welcome to the 2023 Jefferies healthcare conference here in New York. My name is Dennis Ding, mid-cap biotech analyst here at Jefferies. And I have the great pleasure of having the Cara Therapeutics team here with me for a fireside.

So before we really dive into some questions, maybe give a brief overview around the company, the progress you guys have made over the last 12 months and just so everybody's on the same page.

Chris Posner
Cara Therapeutics, Inc. - CEO, President & Director

Sure. Good afternoon, Dennis, and thanks for the invitation to the conference. So Cara Therapeutics, I mean, our strategy is quite simple. We want to be the leader in chronic pruritus. And we've accomplished a lot as a company. We actually have an approved drug called KORSUVA injection that we're actively launching is launching in the US and in Europe.

We have a partner, CSL Vifor, who's in charge of the launch, both in the US and in Europe. And we're expecting an approval in Japan in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot